“…Iron is an attractive element in this respect due to its bioavailability, which substantially limits the toxic effects of its compounds, and the feasible redox chemistry in physiological media, usually involving the +II and +III oxidation states [ 17 , 18 ]. A variety of monoiron complexes have been assessed for the anticancer potential both in vitro and in vivo [ 19 , 20 , 21 , 22 ]. Following the successful experience with ferroquine, a conjugate between ferrocene and the drug chloroquine, which entered phase II clinical trials as an antimalarial agent ( Figure 1 , structure I ) [ 4 , 23 , 24 ], the anticancer properties of related ferrocene derivatives have been intensively investigated (an example in Figure 1 , structure II ) [ 25 , 26 , 27 , 28 ].…”